Publication Details
Abstract
Background: Thyroid nodules are a common finding in clinical settings, with their occurrence ranging approximately from 19% to 68% in the general population when assessed using ultrasonography. Thyroid-stimulating hormone (TSH) is a crucial regulator of thyroid growth and function, acting through TSH receptor activation. Elevated TSH levels have been linked to an increased risk of thyroid cancer, according to several studies. Materials and methods: A total of sixty blood samples were obtained from the laboratories of Kirkuk Hospital between (September 2024 and January 2025). The samples were subsequently categorized into two primary groups: a control group and a group comprising patients with malignant thyroid nodules and hyperthyroidism. Determination of TSH and anti-TPO by one-step sandwich enzyme immunoassay method. Determination of the concentrations of ACE , Progranulin, and Sphingosine by ELISA kit. Results; When comparing to the control group, the patient malignant nodule hyperthyroidism group's TSH and anti-TPO levels significantly increase (P˂0.01). The findings indicated that, in comparison to the control group, the group's ACE activity (IU/L) had significantly increased (P ˂0.01) and FC had significantly increased (P ˂0.05). When comparing to the control group, the levels of progranulin pg/ml in the malignant nodule hyperthyroidism group were significantly higher (P ˂0.001). Conclusion:- The study revealed a significant elevations in current study biomarkers among thyroid cancer patients compared to the control group, TSH and Anti-TPO levels were markedly increased suggesting underlying thyroid dysfunction and autoimmune involvement. ACE activity possibly linked to tumor-associated inflammation, fibrosis, or angiogenesis. Progranulin levels indicating its potential role as a biomarker for aggressive thyroid cancer.